NASDAQ:JUNO Juno Therapeutics (JUNO) Stock Price, News & Analysis → A new way to collect income from stocks (From DTI) (Ad) Free JUNO Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range$86.96▼$86.9650-Day Range$86.96▼$86.9652-Week Range$19.62▼$87.01Volume2 shsAverage Volume5.48 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Juno Therapeutics alerts: Email Address Ad Insider FinancialThousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.Simply tap here now to subscribe and start getting "Insider Financial Advantage" About Juno Therapeutics Stock (NASDAQ:JUNO)Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Its product candidates JCAR017, JCAR014, and JCAR015, as well as an additional early stage product candidate incorporating a fully human binding domain, leverage CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas. Its CAR product candidate JCAR018 targets CD22, a different protein commonly expressed on the surface of B cell leukemias and lymphomas. Its MUC-16 directed product candidate is an armored CAR that secretes the cytokine interleukin 12 (IL-12), which may help to overcome the inhibitory effects that the tumor microenvironment can have on T cell activity.Read More Ad Insider FinancialThousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.Simply tap here now to subscribe and start getting "Insider Financial Advantage" JUNO Stock News HeadlinesApril 9, 2024 | yahoo.comZelda Williams did extensive 'academic study' of '80s films before helming 'Lisa Frankenstein'March 30, 2024 | msn.comMichigan AP names Trey McKenney of Orchard Lake St. Mary's Division 1 basketball Player of the YearApril 23, 2024 | TradeSmith (Ad)The A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...March 27, 2024 | finance.yahoo.comXcell Biosciences Announces New Scientific and Business Advisory BoardMarch 18, 2024 | bizjournals.comOut of the lab and into the factoryMarch 16, 2024 | seekingalpha.comEFTR eFFECTOR Therapeutics, Inc.March 15, 2024 | msn.comMotorcyclist killed in fatal accident near Manatee Avenue, Bradenton police sayFebruary 21, 2024 | msn.comWhat we know about Jeff Bezos’ net worthApril 23, 2024 | TradeSmith (Ad)The A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...February 8, 2024 | uk.finance.yahoo.comMantle Cell Lymphoma Therapeutics Market to Reach $3.29 Billion by 2028 with Innovations in Targeted TherapiesJanuary 31, 2024 | ca.news.yahoo.comZelda Williams Says She Was 'Fascinated’ by Late Dad Robin Williams' Career from Young AgeJanuary 31, 2024 | msn.comHow Zelda Williams Found Humor in TraumaJanuary 16, 2024 | msn.comCovid cases in Stoke-on-Trent right now as 'Juno' strain hits UKJanuary 11, 2024 | uk.finance.yahoo.comVaginitis Therapeutics Global Market Landscape Analysis 2023-2030: New Treatment Avenues and Key Company Innovations Propel the IndustryJanuary 10, 2024 | finance.yahoo.comAutolus Therapeutics announces the appointment of Robert W. Azelby to its Board of DirectorsJanuary 8, 2024 | tmcnet.comBiotech Industry Veterans Jeff Jonas and Al Robichaud Join Cure Ventures as PartnersJanuary 7, 2024 | seekingalpha.comWeek In Review: 2024 Kicks Off With 3 Deals Worth A Total Of $4BDecember 22, 2023 | msn.comTwo dead in McDermot Avenue fire, cause under investigationDecember 12, 2023 | bbc.comElliot Page: Juno actor to divorce Emma PortnerDecember 5, 2023 | finance.yahoo.comSeattle Children's launches BrainChild Bio to accelerate CAR T-cell therapies for children with brain tumorsDecember 5, 2023 | finance.yahoo.comFirst Patient Enrolled in the PUERTA Phase 2A ARDS Clinical Trial: Treatment with Aqualung Therapeutics ALT-100 mAbDecember 4, 2023 | markets.businessinsider.comTScan Therapeutics Expands Manufacturing Leadership with the Appointment of Justin McCue, Ph.D., as Chief Technology OfficerSeptember 15, 2023 | tmcnet.comRepairon Appoints Co-Founder Dr. Lothar Germeroth as Chief Executive OfficerSeptember 12, 2023 | finance.yahoo.comCARGO Therapeutics Announces Appointment of Michael Ports, PhD, as Chief Scientific OfficerAugust 28, 2023 | msn.comNotch Therapeutics closes Vancouver lab, will focus on Toronto and Seattle officesJuly 20, 2023 | msn.comAffini-T Therapeutics shutting down Seattle labJune 15, 2023 | finance.yahoo.comADC Therapeutics Announces Evolution of Board of DirectorsSee More Headlines Receive JUNO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Juno Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/01/2017Today4/23/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:JUNO CUSIPN/A CIK1594864 Webwww.junotherapeutics.com Phone+1-206-5821600FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableOptionable BetaN/A Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesHoward H. Pien (Age 59)Independent Chairman of the Board Hans Edgar Bishop (Age 53)President, Chief Executive Officer, Director Sunil Agarwal M.D. (Age 47)President of Research & Development Steven D. Harr M.D. (Age 46)Chief Financial Officer, Head of Corporate Development Hyam I. Levitsky M.D (Age 54)Executive vice president - Research, chief scientific officer Robert W. Azelby (Age 49)Executive Vice President, Chief Commercial Officer Ann Lee Ph.D.Executive Vice President - Technical OperationsPatrick Y. Yang (Age 69)Executive Vice President Cynthia ElkinsChief Information OfficerBernard J. Cassidy (Age 62)General Counsel, Secretary More Executives JUNO Stock Analysis - Frequently Asked Questions How were Juno Therapeutics' earnings last quarter? Juno Therapeutics Inc (NASDAQ:JUNO) released its quarterly earnings data on Wednesday, November, 1st. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, beating the consensus estimate of ($0.80) by $0.07. The biopharmaceutical company earned $44.80 million during the quarter, compared to the consensus estimate of $18.12 million. The business's revenue was up 115.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.57) earnings per share. What other stocks do shareholders of Juno Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Juno Therapeutics investors own include (KITE) (KITE), bluebird bio (BLUE), Gilead Sciences (GILD), Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), TherapeuticsMD (TXMD), Incyte (INCY), Alibaba Group (BABA) and Heritage-Crystal Clean (HCCI). When did Juno Therapeutics IPO? Juno Therapeutics (JUNO) raised $153 million in an initial public offering (IPO) on Friday, December 19th 2014. The company issued 9,300,000 shares at $15.00-$18.00 per share. Morgan Stanley, J.P. Morgan and Goldman Sachs acted as the underwriters for the IPO and Leerink Partners was co-manager. This page (NASDAQ:JUNO) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Juno Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
